Revvity, Inc., announced a new license agreement with AstraZeneca for the technology underlying its Pin-point™ base editing system, a next-generation modular gene editing platform with a strong safety profile.
Revvity Announces New License Agreement for Next-Generation Base Editing Technology Read More »
Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that England’s National Institute for Health and Care Excellence has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.
GenScript’s new life-science building in Zhenjiang, Jiangsu, China spans 91,310 sq. ft. and is ISO 9001 certified; highly automated clean-room facilities offer fast-turnaround, high-purity oligonucleotide and peptide synthesis service for R&D and preclinical applications.
GenScript Expands Peptide and Oligonucleotide Production Facility in China Read More »
Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation.
Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, will present preclinical research showing the precise genome engineering of human B cells to express diverse therapeutic proteins using the company’s proprietary platform.
ImaginAb, Inc. announced lead selection and progression to IND-enabling studies of IAB56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors.
Adicet Bio, Inc. announced preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy taking place from May 16-20, 2023, in Los Angeles, CA.
Syngenta Group has withdrawn its STAR Market IPO application and will immediately apply for a public listing on the main board at the Shanghai Stock Exchange.
Chroma Medicine, Inc. announced in vivo data that demonstrate 99% silencing of two distinct targets and compelling proof-of-concept for its epigenetic editing platform.
FzioMed, Inc., a global leading surgical biomaterials company focused on spine, orthopedic, peritoneal and gynecological surgery, announced the appointment of industry veteran Alex DiNello to its Board of Directors whose appointment became effective May 1, 2023.
FzioMed Announces Addition of Industry Veteran to its Board of Directors Read More »
